Risk of Delaying or Omitting Mineralocorticoid Receptor Antagonists in Heart Failure

Despite strong class I, level A recommendations from major clinical guidelines, the early initiation and optimization of mineralocorticoid receptor antagonists (MRAs) in heart failure (HF) with reduced ejection fraction (HFrEF) remain suboptimal. MRAs, including spironolactone and eplerenone, provide significant morbidity and mortality benefits, particularly when introduced early in high-risk scenarios such as acute myocardial infarction (AMI) and acute decompensated heart failure (ADHF). Evidence from landmark trials and real-world registries underscores that early MRA therapy reduces cardiovascular events, prevents adverse ventricular remodeling, and lowers sudden cardiac death risk. Delaying or omitting MRAs, even by a few weeks, is associated with increased mortality, recurrent hospitalizations, and irreversible cardiac damage. Clinical evidence demonstrated that early aldosterone blockade exerts rapid and sustained benefits, often within days of initiation. Early initiation and aggressive optimization of MRAs must be prioritized in HFrEF management to fully realize their life-saving potential.